Pharvaris raises $66M series B for clinical development of oral HAE therapy

Pharvaris will use its new $66 million series B round to fund early clinical development of its lead compound, an oral small molecule that could give HAE patients an

Read the full 299 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE